Oxford Cannabinoid Technologies, which develops non-opioid pain pharmaceuticals, is analysed by Proactive Research analyst John Savin.
He talks through the two lead products, which are heading for clinical development: Firstly OCT461201, an oral product to relieve the peripheral nerve pain caused by cancer chemotherapy, and secondly OCT130401, a fast relief inhaled therapy for sudden onset, facial-pain condition.
"It's a really interesting business," adds Savin.